ChromoCure, Inc. Begins Public Filings Reporting With the OTC Disclosure Service

RENO, NV--(Marketwire - July 16, 2009) -

ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it subscribed to the OTC Disclosure Service to provide regular disclosures and transparency to investors. Regular public disclosure and financial reporting enhances the Company’s credibility among both industry peers and public investors.

The company will timely file current disclosures and financial information for 2009.

Investors can access the Company’s public filings at www.pinksheets.com under the Company’s “Filings” tab.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company’s systems measure the unique genomic characteristic common to all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.

The Company’s technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company’s website version of this press release contains various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.